ArticleJournal of clinical medicine2023
Epidemiological and Clinical Characteristics of Adult and Pediatric Patients with Chronic Spontaneous Urticaria.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Real-world treatment patterns and healthcare utilization following omalizumab initiation in chronic spontaneous urticaria: a nationwide Brazilian cohort study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Risk of Abnormal Uterine Bleeding in Women with Chronic Spontaneous Urticaria: Korean Nationwide Population-Based Cohort.Journal of clinical medicine · 2026Article
- Evidence-Based Clinical Recommendations on the Appropriateness of Prescriptions and Diagnostic Tests in Paediatric Allergology: Focus on IgE-Mediated and Non-IgE Mediated Food Allergy, Eosinophilic Gastrointestinal Disease, Urticaria, Angioedema and Atopic Dermatitis.Children (Basel, Switzerland) · 2026Review
- Diagnosis and Management of Comorbid Autoimmune Disorders in Children with Chronic Spontaneous Urticaria.Journal of inflammation research · 2026Review
- Expanding treatment options in chronic spontaneous urticaria: the emerging role of dupilumab.Annals of medicine and surgery (2012) · 2026Article
- Quality of life, sleep, and psychological well-being in chronic spontaneous urticaria patients receiving omalizumab: a case-control study.Archives of dermatological research · 2025Article
- Autoimmune Thyroid Diseases in Chronic Spontaneous Urticaria: The Role of Hormones, Anti-Thyroid Antibodies, and Ultrasound.Diagnostics (Basel, Switzerland) · 2025Article
- <italic>FCGR3A</italic> Drives Innate Immune Activation via M1 Macrophage Polarization in Pediatric IBD.Journal of innate immunity · 2025Article
- Factors associated with quality of life of chronic spontaneous urticaria patients in a Vietnamese population.PloS one · 2025Article
- Evaluation of antihistamine-refractory chronic urticaria patients who used biological agent treatment in terms of cardiovascular risk.Postepy dermatologii i alergologii · 2024Article
- Serum Concentration of IL-5 Receptor (IL-5R) and Associations with Disease Severity in Patients with Chronic Spontaneous Urticaria (CSU) and Atopic Dermatitis (AD).International journal of molecular sciences · 2024Article
- Evaluation of Bilastine's Efficacy and Safety in Treating Chronic Idiopathic Urticaria in Iraqi Patients.Medical journal of the Islamic Republic of Iran · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic spontaneous urticaria (CSU) is when lesions occur for ≥6 weeks. However, its underlying mechanism remains unclear. CSU prevalence is similar in adult and pediatric patients; nevertheless, few data are available on CSU characteristics in pediatric patients. We aimed to describe the epidemiology, clinical features, and treatment approach of CSU in pediatrics and adults. In this cross-sectional study, 193 patients with CSU were treated at the Sheba Medical Center, Israel, in 2009-2022. The information collected includes age at diagnosis, reported triggers, atopic co-morbidities, autoimmune co-morbidities, treatments and their response, family background, laboratory tests, and follow-up duration. The study group was divided into pediatrics (aged ≤ 18) and adults. Metabolic syndrome was most prevalent in adults as against atopy in pediatrics. Autoimmune co-morbidities were observed in 34.7% and 34.8% of adults and pediatrics, respectively. Inflammatory bowel disease and thyroid disease were the most common in pediatrics and adults, respectively. Systemic treatments other than antihistamines were administered more frequently in adults. Adults with autoimmune disease required second-line treatment with immunomodulators compared to those without it. Co-morbidities were more common in adults than in pediatrics. Patients with autoimmune co-morbidities may be more challenging to manage; thus, escalation to biologics should be considered soon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.